GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I'd seen in the stock before that. The post GSK’s share price looks a steal to me ...
GSK ha anunciado hoy que la Agencia Europea de Medicamentos (EMA) ha aceptado revisar su solicitud de ampliar el uso de ...
Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...
GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...
Recent health news highlights a 10% rise in child TB infections in Europe, detected mammal bird flu cases, and economic ...
Current health news highlights a 10% rise in child TB infections in Europe, a new drug review by European regulators, the ...
Zacks Investment Research on MSN9d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPDGSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...
GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...
GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...
El biológico, ya aprobado para el asma grave, podría convertirse en el primer tratamiento mensual autorizado para esta forma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback